Hepatitis B vaccine: safety study in anti-HBs seropositive human volunteers.
HBsAg, which has been purified from HBsAg and HBeAg positive plasma, was repeatedly applied to human volunteers, who were seropositive for anti-HBs. The intramuscular or subcutaneous injections caused a clear booster effect on anti-HBs concentrations in serum. The injections were well tolerated. Only minor local side effects occurred. Vaccination left serum transaminase activities unaffected. None of the volunteers developed serologic or clinical signs related to viral hepatitis.
D000328:Adult; D006510:Hepatitis B Antibodies / Q000032:analysis*; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D017325:Hepatitis B Vaccines; D006801:Humans; D008297:Male; D008875:Middle Aged; D014765:Viral Vaccines / Q000009:adverse effects / Q000276:immunology / Q000592:standards*
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D014765:Viral Vaccines